These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review. Bjørklund G; Dadar M; Anderson G; Chirumbolo S; Maes M Pharmacol Res; 2020 Nov; 161():105065. PubMed ID: 32652199 [TBL] [Abstract][Full Text] [Related]
92. PPAR-γ: therapeutic prospects in Parkinson's disease. Carta AR Curr Drug Targets; 2013 Jun; 14(7):743-51. PubMed ID: 23469878 [TBL] [Abstract][Full Text] [Related]
93. Neuroprotection for Parkinson's disease: a new approach for a new millennium. Drukarch B; van Muiswinkel FL Expert Opin Investig Drugs; 2001 Oct; 10(10):1855-68. PubMed ID: 11772291 [TBL] [Abstract][Full Text] [Related]
97. Microglial ion channels as potential targets for neuroprotection in Parkinson's disease. Richardson JR; Hossain MM Neural Plast; 2013; 2013():587418. PubMed ID: 24288626 [TBL] [Abstract][Full Text] [Related]
98. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Marsden CD; Olanow CW Ann Neurol; 1998 Sep; 44(3 Suppl 1):S189-96. PubMed ID: 9749592 [TBL] [Abstract][Full Text] [Related]
99. Dopamine D3 agonists in the treatment of Parkinson's disease. Das B; Modi G; Dutta A Curr Top Med Chem; 2015; 15(10):908-26. PubMed ID: 25832718 [TBL] [Abstract][Full Text] [Related]
100. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Singhal NK; Srivastava G; Agrawal S; Jain SK; Singh MP Mol Neurobiol; 2012 Feb; 45(1):186-99. PubMed ID: 22198804 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]